NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Myrobalan Therapeutics

Myrobalan Therapeutics

Private
Medford, MassachusettsHealthcare & Life Scienceshttps://myrotx.com/

Last Round

Grant

Mar 13, 2025

Total Funding Raised

$54.25M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Myrobalan Therapeutics is a biotechnology company that develops oral neurorestorative therapies designed to reverse the underlying pathologies of brain dysfunctions and central nervous system conditions.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

small molecule drugsneurodegenerative diseaseremyelination therapyCNS therapeuticsneuroinflammation therapybrain-penetrant drugsmultiple sclerosisneurorestorative drugsoral therapeuticsdemyelinating disordersneuroscience biotechcentral nervous systemCNSpreclinical biotechnologyAlzheimer's diseaseALSGPR17 antagonist

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Myrobalan Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Myrobalan Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Myrobalan Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 13, 2025
GrantFeb 7, 2024
Series AJan 10, 2024
SeedApr 1, 2022
SeedSep 1, 2021

Key People

Founding team and executive leadership

Jing Wang

Co-Founder & CEO

Founding Team

Myrobalan Therapeutics Investors

Notable investors and investment history

Myrobalan Therapeutics investors
InvestorRounds
The ALS AssociationGrant
Bencao CapitalSeries A, Seed
Co-Win VenturesSeries A
National MS SocietyGrant
Ab Magnitude Ventures GroupSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 63% MoM.

  • Feb 23, 2026

    Partnered with University of Colorado Anschutz School of Medicine for preclinical research.

Myrobalan Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Myrobalan Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Myrobalan Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMedford, Massachusetts
Employee Range15
Year Founded2021
Last FundingMar 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.